key: cord-0876443-cy0omph6 authors: Arora, Umang; Priyadarshi, Megha; Katiyar, Varidh; Soneja, Manish; Garg, Prerna; Gupta, Ishan; Bharadiya, Vishwesh; Berry, Parul; Ghosh, Tamoghna; Patel, Lajjaben; Sarda, Radhika; Garg, Shreya; Agarwal, Shubham; Arora, Veronica; Ramprasad, Aishwarya; Kumar, Amit; Garg, Rohit Kumar; Kodan, Parul; Nischal, Neeraj; Singh, Gagandeep; Jorwal, Pankaj; Kumar, Arvind; Baitha, Upendra; Meena, Ved Prakash; Ray, Animesh; Sethi, Prayas; Xess, Immaculata; Vikram, Naval; Sinha, Sanjeev; Biswas, Ashutosh; Thakar, Alok; Bhatnagar, Sushma; Trikha, Anjan; Wig, Naveet title: Novel risk factors for Coronavirus disease-associated mucormycosis(CAM): a case-control study during the outbreak in India date: 2021-12-30 journal: J Infect DOI: 10.1016/j.jinf.2021.12.039 sha: 1246fcf1a2b548d6200af98e72517893df393d38 doc_id: 876443 cord_uid: cy0omph6 BACKGROUND: The epidemiology of the Coronavirus-disease associated mucormycosis (CAM) syndemic is poorly elucidated. We aimed to identify risk factors that may explain the burden of cases and help develop preventive strategies. METHODS: We performed a case-control study comparing cases diagnosed with CAM and taking controls as recovered COVID 19 patients who did not develop mucormycosis. Information on comorbidities, glycemic control, and practices related to COVID-19 prevention and treatment was recorded. Multivariate regression analysis was used to identify the independent predictors. RESULTS: A total of 352 patients (152 cases and 200 controls) diagnosed with COVID-19 during April-May 2021 were included. In the CAM group, symptoms of mucormycosis began a mean of 18.9 (SD 9.1) days after onset of COVID-19, and predominantly rhino-sinus and orbital involvement was present. All, but one, CAM cases had conventional risk factors of diabetes and steroid use. On multivariable regression, increased odds of CAM were associated with the presence of diabetes (adjusted OR 3.5, 95%CI 1.1-11), use of systemic steroids (aOR 7.7,95% CI 2.4-24.7), prolonged use of cloth and surgical masks (vs. no mask, aOR 6.9, 95%CI 1.5-33.1), and repeated nasopharyngeal swab testing during the COVID-19 illness (aOR 1.6,95% CI 1.2-2.2). Zinc therapy was found to be protective (aOR 0.05, 95%CI 0.01-0.19). Notably, the requirement of oxygen supplementation or hospitalization did not affect the risk of CAM. CONCLUSION: Judicious use of steroids and stringent glycemic control are vital to preventing mucormycosis. Use of clean masks, preference for N95 masks if available, and minimizing swab testing after the diagnosis of COVID-19 may further reduce the incidence of CAM. Umang  A case-control study was performed to assess factors associated with occurrence of Coronavirusdisease associated mucormycosis, an invasive fungal infection that led to a syndemic during the second wave of COVID-19 in India.  Diabetics and patients receiving steroid therapy are at increased risk of CAM.  The role of mask type and hygiene, repeated nasopharyngeal swab testing and zinc supplementation as modifiable factors to prevent CAM merits further study. Background: Patients above 18 years of age diagnosed with CAM were identified as cases. CAM was defined as mucormycosis based on clinico-radiological or microbiological evidence with fungal staining or culture. As per the consensus criteria, definite mucormycosis was defined as the demonstration of aseptate ribbonlike broad hyphae on histopathology of biopsied samples (with or without culture) and probable mucormycosis patients with suggestive clinical symptoms and radiologic imaging along with isolation of Mucorales from nonsterile samples such as swab sample from the nasal area. 4 Controls were defined as patients who recovered from COVID-19 with symptom onset at least one month before recruitment and no clinical features suggestive of CAM. Controls were selected consecutively from records of the ward as well as outpatient clinic. The case definition by the World Health Organization(WHO) for definite or probable cases of SARS-CoV-2 infection was used to select both cases and controls, including requirement for a positive test among RT-PCR, rapid antigen test, or CB-NAAT. 5 We limited both cases and controls to those who developed symptoms or test positivity of COVID-19 illness during the months of April-May 2021 to account for potential confounding factors including change in the viral strains. Patients who did not give consent were excluded. We assessed the risk factors associated with the development of mucormycosis in patients with COVID- Figure 2 . N95 mask use was more frequent among controls (42.5% vs 18%), while CAM patients tended to use cloth masks(52% vs 36%). (Table 3 ) The use of N95 masks was observed to be protective in comparison to not using a mask (p<0.05). Use of cloth masks more than four hours(4-6 hours, p=0.002; >6 hours, p<0.0001) and use of surgical masks for more than six hours (p=0.002)was found to be associated with a higher risk of CAM when compared to the use of respective masks for less than two hours or N95 for any duration. (Figure 3 ) The findings were similar even after excluding health care workers(n=40) as confounders, who were more limited to the control group and used N95 masks exclusively. Due to diversity in practices of mask disinfection, reuse, and discarding, this information could not be analyzed. The two groups did not differ in their practice of steam inhalation vis-a-vis the frequency of steam inhalation and the time of starting steam inhalation in relation to the onset of COVID-19 symptoms. Mask use practices were divided into four risk categories based on the univariate analysis. The use of N95 masks for any duration was considered as low risk, while use of no mask was categorized separately. Use of surgical masks for more than 6 hours or cloth masks for more than 4 hours constituted the third group with the highest risk, while shorter duration of either mask use (surgical mask <6 hours or cloth masks <4 hours) formed the fourth group. The multivariable model was limited to patients with symptomatic COVID-19 since the hospitalization policy excluded admission of asymptomatic COVID-19 patients. We also excluded residence in rural area in the model as we were unable to capture information on the household or environment determinants contributing to this risk. Risk factors that were found to be independently associated with the risk of development of mucormycosis in multivariable analysis were diabetes, mild and moderate (vs severe) COVID-19 disease, highest blood glucose of more than 200 mg/dL at any time during COVID-19 illness, the number of swab tests performed, and systemic steroid use. (Table 4 ) The use of zinc was found to be protective. Among mask use, prolonged use of surgical masks (>6 hours) and cloth masks (>4 hours) were associated with increased odds of CAM (6.9, 95% CI 1.5 -33.1, p=0.02) compared to no mask use. A shorter duration of cloth or surgical mask usage was associated with higher odds of CAM vs N95 masks (4.9, 95% CI 1.9 -16, p<0.001), but lower than prolonged surgical or cloth mask use (0.28, 95% CI 0.08 -0.97, p=0.046). The findings were consistent after subgroup analysis of the same mask use categories among patients residing in urban areas. Mucormycosis is a sporadic disease occurring almost exclusively in immunocompromised patients. 8 The sudden spike in the incidence of CAM in the wake of the COVID-19 pandemic raises the possibility that COVID-19 infection may itself predispose to mucormycosis. This may occur directly through its impact on immune system or indirectly due to the interventions related to COVID-19 prevention and management. Even in the pre-COVID-19 era, India reported the highest prevalence of mucormycosis worldwide, nearly 70 times that of global estimates. 2 This disproportionate burden has been attributed to the high prevalence of both patient factors (diabetes) and environmental factors (hot humid environment). 9 Residence in a rural area was more common among CAM cases, possibly because of a referral bias for a difficult to treat disease. Our study found that CAM was more common in males in the fifth and sixth decades. The disease occurred three weeks after the onset of COVID-19 symptoms and involved mainly the rhinoorbital areas, similar to reported literature. 1 Poor glycemic control, systemic steroid therapy, and presence of diabetes are associated with increased risk of CAM. 9 However,2-32% of reported cases of CAM may lack any of these associations. 1,10 This is a departure from our finding, where a single case of CAM(out of 152)was neither diabetic nor had received steroids. Neutrophils and macrophages kill sporangiospores and hyphal forms of Mucoralesand constitute the major barrier to invasion. 11 An adaptive immune response is stimulated characterized by strong Th-17 activation that initiates a stronger neutrophil response. Simultaneously, the immune response to COVID-19 is complex. Neutrophils in the nasopharyngeal epithelium demonstrate markers of premature activation, 12 These abnormalities tend to peak in the second week, which may explain the clustering of cases of CAM in the third week after COVID-19 symptom onset. Also, endothelial dysfunction and vasculopathy due to COVID-19 may support angioinvasion and the spread of Mucorales. 14 Influence of the mutated variants of COVID-19 on the development of CAM remains to be explored. Diabetes or impaired glucose tolerance is reported in the majority of patients with mucormycosis with or without COVID-19. Hyperglycemia inhibits neutrophil chemotaxis, phagocytosis by macrophages, and degranulation of NK cells. 15 It promotes surface glucose-regulated protein (GRP78) expression on the endothelium which is essential for invasion by Mucorales. 16 The prevalence of diabetes in CAM was higher than historical cohorts of mucormycosis not associated with COVID (92% vs 76%). 17 Newly detected diabetes is reportedly more prevalent in CAM compared to mucormycosis not associated with COVID-19 (21% vs 10%, p=0.02). 1 However, previous studies did not report measuring HbA1c for mucormycosis patients, which may have led to the underreporting of diabetes in previous cohorts. Additionally, supra-physiological stress during COVID-19 illness and viral-mediated islet cell damage may contribute to hyperglycemia. 18 Diabetic ketoacidosis is detected in 8-22% of mucormycosis patients at presentation, being a rare occurrence in the natural history of type 2 diabetes otherwise. 19 However, DKA was previously identified to be uncommon among CAM compared to mucormycosis not associated with COVID-19 (8.6% vs 27%, p<0.001). 1 Additionally, we found a progressively higher risk of mucormycosis with higher blood glucose levels suggesting a dose-response relationship, with those having blood glucose >400 mg/dL, at the highest risk. Prolonged corticosteroid intake is a risk factor for the development of mucormycosis. 16 This may be mediated by inhibition of macrophages and neutrophils and the tendency to cause hyperglycemia. Steroidinduced hyperglycemia (SIH) primarily raises post-prandial glucose levels and their measurement is imperative for glycemic control. High dose steroid use for short term does not raise HbA1c in those without diabetes or prediabetes, and higher pre-steroid therapy HbA1c predicts the development of SIH. 20 We found that patients in the CAM group had 7. Although studies on zinc in COVID-19 have shown equivocal results, it is widely used owing to its good safety profile and low cost. 22 Zinc is essential for normal functioning of immune cells in our body. Further, zinc supplementation has been hypothesized to reduce pro-inflammatory cytokines, blunt lymphopenia, and reduce airway inflammation in COVID-19 patients. 23 We found that zinc supplementation was associated with a significant reduction in the risk of mucormycosis, but a doseresponse relationship was not seen. This may be related to the beneficial immuno-modulatory role of zinc, especially in COVID-19 patients who are likely to be deficient. 24 Prospective clinical trials are needed to confirm these findings. More than one-third of patients in the CAM arm (37.7%) had recovered from moderate to severe COVID- 19 . This is in contrast to the COSMIC study in which 72% of patients recovered from moderate or severe COVID-19 disease. 10 Our results suggest that severe disease was associated with a lower risk of developing mucormycosis. This may be related to the selection bias of recruiting mainly hospitalized patients in both arms, which may have enriched the control arm with patients having severe disease. Secondly, survivorship bias may have played a role since patients of severe COVID-19 may have died prior to the development of symptoms of CAM. A prospective study design is required to evaluate the same. The overall proportion of patients requiring oxygen therapy as well as the duration of oxygen therapy was similar in cases and controls. However, exposure to high flow oxygen devices was lower in the CAM group in line with the proportion of patients with severe COVID-19 illness. COVID-19 disease severity correlates with raised ferritin levels reflecting the inflammatory state. Ferritin levels were found to be higher in cases of CAM compared to controls. Iron uptake correlates linearly with the growth of Rhizopus in serum and is essential for its pathogenicity in the presence of siderophores. 25 Higher ferritin levels have been associated, albeit weakly, with the risk of mucormycosis in hematopoietic allograft recipients. 26 The pathogenetic role of iron metabolism in mucormycosis merits further evaluation as elevated ferritin does not directly imply increased intracellular iron available to Rhizopus, the dominant species responsible for mucormycosis, is thermotolerant and grows well at or above body temperature and in a moist environment. 27 This prompted us to evaluate the role of mask use in modulating the risk of CAM. The use of surgical or cloth masks for prolonged periods was found to be associated with an increased risk of CAM in our study. It has been shown that temperature of the perioral skin rises after use of face masks for even one hour. 28 Cloth masks increase the risk of respiratory tract infections compared to other masks, as well as no mask use. 29 The reuse of cloth masks, variation in effective cleaning practices, and retention of moisture are proposed as factors for this increase.N95 masks are made of fluid-resistant synthetic materials that inhibit the growth of fungal elements. 30 Organic cloths used commonly in Indian masks, like cotton and silk, do not share similar properties. The organic matter contaminating usual cloth masks may allow implantation of Mucorales spores within the nasal cavity. Also, duration of mask use may be a surrogate for increased outdoor exposure and consequently soil and dust that harbor Mucorales spores. Our findings may require further evaluation in prospective studies since a large proportion of our controls used N95 masks (42.5% vs 18% in CAM), probably due to the disproportionate number of healthcare workers in that arm (n=40). We also could not obtain reliable information about the frequency of discarding or laundering of masks, socio-cultural factors influencing the preferred mask type, or change in mask use practices during recovery from COVID-19at a time when CAM is in incubation. Nevertheless, the use of unclean cloth or surgical masks should be avoided. Physical factors that may increase the risk of mucormycosis were also evaluated. Repeated nasopharyngeal swab testing for COVID-19, if done more than twice, was found to be independently associated with a higher risk of CAM. Development of cutaneous mucormycosis at sites of local trauma such as infected intravenous catheters, dressings, and needles is well reported. 31 Repeated nasopharyngeal swab testing may cause micro-trauma to nasal and nasopharyngeal mucosa, predisposing to angioinvasion. Similarly, steam inhalation has been hypothesized to cause heat injury to the nasal mucosa, whereas we did not find any association between the risk of CAM and frequent steam use or continued steam use beyond recovery from COVID- 19. 32 Our study is the first large case-control study evaluating the risk factors specific to the development of CAM. We hypothesized and investigated several risk factors for CAM unique to the prevention and management of COVID-19, beyond those already established for mucormycosis prior to the COVID-19 pandemic. Information was obtained and corroborated from several sources to mitigate recall bias and missing information. Restricting ourselves to the second wave of COVID-19 between April-May 2021 prevented discrepancies in healthcare access due to the overwhelming rise in cases. The peak incidence of COVID-19 symptoms for both groups occurred on 20 th April 2021 ( Figure 1A) , coinciding with the peak number of 28,395 COVID-19 cases reported in a single day in the region of Delhi, India as per crowdsourced trackers. 33 However, this study has a few limitations. Firstly, recall bias is inherent to the casecontrol study design and cannot be completely eliminated. Specifically, duration of mask use along with discarding and laundering practices is subject to recall and interviewer bias. Further prospective studies would be required to affirm its association with increased risk of CAM, although this may be impractical. Secondly, differences in COVID-19 treatment practices may exist since CAM cases were treated at other hospitals while controls were mainly treated at our tertiary care center. Patients with CAM may have differed from control arm with respect to residence in rural areas due to a possible referral bias, since treatment of CAM was limited to select tertiary centers. Thirdly, since it was a retrospective study, the robustness of our findings decreased due to lower sample size available for multivariable modeling in view of missing information particularly for blood glucose, HbA1c, and ferritin. Fourth, cases of CAM may occur infrequently beyond 30 days of COVID-19 onset (n=10, 6.6%) and thus controls may remain at-risk of CAM. However, none of the controls have notified the authors of the occurrence of CAM even after study completion. In conclusion, CAM is strongly associated with diabetes, poor glycemic control, and systemic steroid use. The requirement of oxygen therapy and hospitalization for COVID-19 did not affect the risk of CAM. Novel risk factors identified in our study include prolonged use of cloth and surgical masks vis-a-vis N95 masks and repeated nasopharyngeal swab testing. These are potentially modifiable and merit further prospective research. Funding source: None to declare Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India. Emerg Infect Dis Epidemiology of Mucormycosis in India Black fungus: Here is a list of states with highest number of mucormycosis cases Hindustan Times Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium WHO COVID-19 Case definition Diagnosis and Classification of Diabetes Mellitus. Diabetes Care A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India Mucormycosis in India: unique features Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India -Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC) Innate and Adaptive Immunity to Mucorales. J Fungi Basel Switz Neutrophils in COVID-19. Front Immunol Longitudinal analyses reveal immunological misfiring in severe COVID-19 Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches Type 2 Diabetes and its Impact on the Immune System Pathogenesis of Mucormycosis Mucormycosis--from the pathogens to the disease New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K. Diabetes Care Diabetic ketoacidosis. Nat Rev Dis Primer Outpatient management of steroid-induced hyperglycaemia and steroid-induced diabetes in people with lymphoproliferative disorders treated with intermittent high dose steroids Dexamethasone in Hospitalized Patients with Covid-19 Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial Does Evidence Exist to Blunt Inflammatory Response by Nutraceutical Supplementation during COVID-19 Pandemic? An Overview of Systematic Reviews of Vitamin D, Vitamin C, Melatonin, and Zinc. Nutrients Enhancing immunity in viral infections, with special emphasis on COVID-19: A review Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies Impact of pretransplant serum ferritin level on risk of invasive mold infection after allogeneic hematopoietic stem cell transplantation Zygomycetes in human disease Facial Skin Temperature and Discomfort When Wearing Protective Face Masks: Thermal Infrared Imaging Evaluation and Hands Moving the Mask A cluster randomised trial of cloth masks compared with medical masks in healthcare workers Last-resort strategies during mask shortages: optimal design features of cloth masks and decontamination of disposable masks during the COVID-19 pandemic The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports Intercepting the deadly trinity of mucormycosis, diabetes and COVID-19 in India Coronavirus in India The authors would make the data available on specific requests keeping patient confidentiality in view. The study was approved by the Institute Ethics Committee, AIIMS, Delhi, India. [IECPG-353/28.05. 21] The authors declare that they have no competing interests.